Cerebral Amyloid Angiopathy-Related Inflammation: Current Status and Future Implications

0
0
0

Cerebral Amyloid Angiopathy-Related Inflammation: Current Status and Future Implications

Cerebral amyloid angiopathy-related inflammation (CAA-RI) represents a rare but increasingly recognized subtype of cerebral amyloid angiopathy (CAA), characterized by vascular amyloid-β (Aβ) deposition and perivascular or transmural inflammatory infiltrates. CAA-RI encompasses two pathological subtypes: inflammatory cerebral amyloid angiopathy (ICAA), marked by non-destructive perivascular inflammation, and Aβ-related angiitis (ABRA), involving angio-destructive transmural inflammation. Although histopathological confirmation via biopsy or autopsy remains the diagnostic gold standard, advancements in neuroimaging and biomarker studies have enabled non-invasive clinical diagnoses. This review synthesizes current knowledge on CAA-RI, addressing its pathophysiology, clinical-radiological features, diagnostic challenges, therapeutic strategies, and unresolved research questions.

Pathogenesis and Pathology

CAA-RI arises from Aβ deposition in the media and adventitia of cortical and leptomeningeal vessels, triggering an autoimmune response. The pathogenesis is hypothesized to involve an aberrant immune reaction against vascular Aβ, mirroring the mechanism observed in amyloid-related imaging abnormalities (ARIA) associated with anti-Aβ immunotherapy in Alzheimer’s disease (AD). APOE ε4 allele homozygosity is strongly linked to CAA-RI, found in 76.9% of patients, compared to 5.1% in non-inflammatory CAA. This genotype promotes Aβ accumulation and pro-inflammatory effects, heightening susceptibility to CAA-RI.

Histologically, CAA-RI exhibits Aβ deposits confirmed by Congo red staining with green birefringence under polarized light. Inflammatory infiltrates include CD3+ T cells, CD68+ macrophages, multinucleated giant cells, and fewer B cells. ABRA cases often show granulomatous inflammation and fibrinoid necrosis, overlapping with features of primary angiitis of the central nervous system (PACNS). However, unlike PACNS, CAA-RI strictly involves Aβ-laden vessels, and spinal cord manifestations are absent.

Clinical Presentation

CAA-RI predominantly affects older adults (mean age: 67 years) without gender predilection. Subacute cognitive decline and behavioral changes are the most frequent symptoms (48%), followed by seizures (32%), headaches (32%), encephalopathy (27%), and focal neurological deficits (16%). Visual impairments, involuntary movements, and atypical presentations mimicking tumors or uveitis have also been reported. Rapid progression over weeks to months necessitates timely differentiation from conditions like posterior reversible encephalopathy syndrome (PRES) or malignancies.

Neuroimaging Features

Brain MRI is pivotal for diagnosing CAA-RI. Key findings include:

  1. T2/FLAIR Hyperintensities: Patchy or confluent white matter hyperintensities (WMH) with vasogenic edema, often asymmetric and occasionally mass-like. These lesions show reduced diffusion restriction, distinguishing them from acute ischemia.
  2. Strictly Lobar Microbleeds (CMBs): Detected via susceptibility-weighted imaging (SWI) or T2*-weighted sequences. CAA-RI patients exhibit higher CMB burden compared to non-inflammatory CAA, though absence of CMBs does not exclude the diagnosis.
  3. Cortical Superficial Siderosis (cSS): A marker of prior bleeding, present in 75% of cases.
  4. Leptomeningeal or Parenchymal Enhancement: Observed in 70% of cases, particularly in ABRA, reflecting blood-brain barrier disruption.

Amyloid positron emission tomography (PET) demonstrates cortical Aβ deposition, aiding differentiation from PACNS. Magnetic resonance angiography (MRA) is typically unremarkable due to small-vessel involvement.

Biomarkers and Laboratory Findings

  • Cerebrospinal Fluid (CSF): Elevated protein levels (80%), pleocytosis (44%), and reduced Aβ42/Aβ40 ratios are common. Anti-Aβ autoantibodies are elevated acutely and decline post-immunotherapy, serving as potential diagnostic and therapeutic markers.
  • Serology: Inflammatory markers like C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are elevated in 60% and 37.5% of cases, respectively.

Diagnostic Criteria

The Boston criteria and Auriel criteria enable non-invasive diagnosis:

  1. Probable CAA-RI: Requires all of the following:
    • Acute/subacute clinical symptoms (cognitive decline, seizures, headache).
    • T2/FLAIR hyperintensities with vasogenic edema.
    • Strictly lobar CMBs or cSS.
    • Absence of alternative causes.
  2. Possible CAA-RI: Includes atypical presentations without full imaging criteria.

Biopsy is recommended for non-responsive cases or diagnostic uncertainty, targeting enhancing or edematous regions to avoid sampling error.

Differential Diagnoses

CAA-RI mimics several conditions:

  • PRES: Shares T2 hyperintensities but lacks CMBs/cSS and often associates with hypertension.
  • Primary CNS Lymphoma: Enhances homogeneously, while CAA-RI shows patchy enhancement.
  • PACNS: Affects younger patients, involves spinal cord, and lacks Aβ deposition.
  • Neurosarcoidosis/ADEM: Differentiated via systemic involvement and CSF profiles.

Treatment and Prognosis

Immunosuppression is the cornerstone of therapy:

  • First-line: High-dose corticosteroids (e.g., methylprednisolone 1 g/day for 3–5 days), yielding clinical and radiological improvement in 55% of cases.
  • Refractory/Relapsing Cases: Cyclophosphamide, azathioprine, or mycophenolate mofetil as steroid-sparing agents.

Relapse occurs in 30%–40% of cases, often during steroid tapering. Spontaneous remission is rare (10%). Long-term outcomes vary: 55% achieve remission or mild disability, while 40% progress to severe disability or death. Persistent CMBs may indicate treatment resistance.

Future Directions

Unresolved questions include:

  1. Pathogenic Triggers: Why only a subset of CAA patients develop inflammation.
  2. Genetic Susceptibility: Role of non-APOE genes (e.g., SORL1 variants) and their interaction with Aβ metabolism.
  3. Biomarkers: Validation of CSF anti-Aβ autoantibodies and amyloid PET for early diagnosis.
  4. Therapeutic Optimization: Randomized trials to compare immunosuppressive regimens and evaluate long-term outcomes.
  5. Autoantibody Pathogenicity: Mechanistic studies on anti-Aβ antibodies in driving inflammation.

Conclusion

CAA-RI is a treatable encephalopathy that demands high clinical suspicion in elderly patients with subacute cognitive decline, seizures, or focal deficits. MRI with SWI/FLAIR sequences and APOE genotyping enhance diagnostic accuracy. While immunosuppression improves outcomes, relapses and diagnostic ambiguities underscore the need for multidisciplinary collaboration and translational research.

doi.org/10.1097/CM9.0000000000001427

Was this helpful?

0 / 0